

\*Required Information

## SUBMISSION STATUS

First Submission  Resubmission  Associated Order Number \_\_\_\_\_

## CLINICAL INFORMATION AT TIME OF ORDER

### NODAL STATUS\*

- (NX) Not Submitted or Found  
 (N0) Negative  
 (N1) 1-3 Nodes  
 (N2 or N3) ≥ 4 Nodes  
 Clinical Assessment

### TUMOR INFORMATION\*

- Tumor Size (check one):  
 ≤ 5.0 cm  
 > 5.0 cm  
 Tumor Grade:  1  2  3  
 Clinical Assessment

### HORMONE RECEPTOR STATUS\*

- |      | Positive                 | Negative                 | Equivocal                |
|------|--------------------------|--------------------------|--------------------------|
| ER   | <input type="checkbox"/> | <input type="checkbox"/> |                          |
| PR   | <input type="checkbox"/> | <input type="checkbox"/> |                          |
| HER2 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

## TESTS ORDERED\*

MammaPrint & Blueprint  MammaPrint Only  Blueprint Only  Perform test(s) marked on requisition only

Agendia will perform any test(s) indicated by standing order on file from the ordering physician unless otherwise requested.

## CLIENT INFORMATION\*

Account Name \_\_\_\_\_  
 Account Address \_\_\_\_\_  
 Account City \_\_\_\_\_ Account State \_\_\_\_\_ Account Zip Code \_\_\_\_\_  
 Account Phone \_\_\_\_\_ Account Fax \_\_\_\_\_

## ORDERING PHYSICIAN INFORMATION & SIGNATURE

As the physician of record, I have concluded that the test(s) I am ordering is medically necessary for treatment of this patient. I anticipate that this test(s) will provide prognostic and/or predictive information which has not been obtained already. I confirm the patient consented for this test to be performed for this purpose. This Order form is part of the medical record, is consistent with other entries in the record, and accurately describes the reason(s) I am ordering the tests.  
 If indicated on the Test Request Form that I am ordering the test(s) as part of an authorized clinical trial, I confirm that the patient consented in writing to participate in the clinical trial, and that my ordering of the test(s) for this patient is consistent with the applicable clinical trial protocol.  
 I also confirm that to the extent necessary, and consistent with any applicable clinical trial protocol, the patient consented for Agendia, Inc. to release test information when necessary to obtain reimbursement. In submitting this Order, I acknowledge that I have read and agree to be bound by Agendia's General Terms of Service found here: <https://agendia.com/terms-conditions/general-terms-of-service/>.

Ordering Physician Name\* \_\_\_\_\_  
 Ordering Physician Signature\* \_\_\_\_\_ Ordering Physician Phone \_\_\_\_\_ Date\* \_\_\_\_\_  
 Ordering Physician NPI \_\_\_\_\_ Ordering Physician Fax \_\_\_\_\_ Additional Report Recipient Email/Fax \_\_\_\_\_

## PATIENT INFORMATION\*

Patient Name: Last, First, Middle \_\_\_\_\_  
 Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Country \_\_\_\_\_  
 Date of Birth \_\_\_\_\_ Patient Phone \_\_\_\_\_  
 Gender:  Female  Male  
 MRN: \_\_\_\_\_  
 Hospital Status  Hospital Inpatient  Hospital Outpatient  Non Hospital Patient  
 (Medicare Only) (>24hr Stay)  
 Date of Hospital Discharge: \_\_\_\_\_

## BILLING INFORMATION

**COMPLETE the following & attach copy of face sheet and front and back of insurance card**

Billing Type:  Private Insurance  Medicare  Patient  Bill Client  
Restricted to contracted accounts on file at Agendia  
 Submitting Diagnosis\* \_\_\_\_\_  
*i.e. C50.21*  
 ICD-10 Code\* \_\_\_\_\_  
 Primary Insurance Name\* \_\_\_\_\_ Member ID\* \_\_\_\_\_  
 Prior Auth # (if available) \_\_\_\_\_ Phone\* \_\_\_\_\_  
 Secondary (if applicable)\* \_\_\_\_\_ Member ID\* \_\_\_\_\_  
 Relationship to insured:  Self (skip section)  Spouse  Dependent  
 Other: Insured DOB\* MM/DD/YYYY

## PATHOLOGY INFORMATION\*

Agendia to request specimen from pathology  Ordering physician to request specimen from pathology  
 Facility \_\_\_\_\_  
 Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Country \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_ Email \_\_\_\_\_

Additional Comments

Note: Multiple specimens will be processed in the order indicated below. See reverse side for additional information.  
**PLEASE INCLUDE PATHOLOGY AND IMAGING REPORTS WITH TEST REQUEST**

Collection Date*	Specimen ID*	Specimen Type*	Specimen Site*	Container Type*	Qty*
	1.	<input type="checkbox"/> Core Biopsy <input type="checkbox"/> Surgical <input type="checkbox"/> Other _____	<input type="checkbox"/> Left Breast <input type="checkbox"/> Right Breast <input type="checkbox"/> Other _____	<input type="checkbox"/> Block <input type="checkbox"/> Slides	
	2.	<input type="checkbox"/> Core Biopsy <input type="checkbox"/> Surgical <input type="checkbox"/> Other _____	<input type="checkbox"/> Left Breast <input type="checkbox"/> Right Breast <input type="checkbox"/> Other _____	<input type="checkbox"/> Block <input type="checkbox"/> Slides	
	3.	<input type="checkbox"/> Core Biopsy <input type="checkbox"/> Surgical <input type="checkbox"/> Other _____	<input type="checkbox"/> Left Breast <input type="checkbox"/> Right Breast <input type="checkbox"/> Other _____	<input type="checkbox"/> Block <input type="checkbox"/> Slides	

# TERMS AND CONDITIONS

## AGENDIA, INC. CLINICAL LABORATORY TESTING REQUISITION

### INTENDED USE(S)

MammaPrint® FFPE is a qualitative in vitro diagnostic test, performed in a central laboratory, using the gene expression profile obtained from formalin-fixed paraffin embedded (FFPE) breast cancer tissue samples to assess a patient's risk for distant metastasis within 5 years.

MammaPrint FFPE is performed for breast cancer patients, with Stage I or Stage II disease, with tumor size ≤ 5.0 cm and lymph node negative. The MammaPrint FFPE result is indicated for use by physicians as a prognostic marker only, along with other clinico-pathological factors.

### SPECIAL CONDITIONS FOR USE STATEMENT(S)

MammaPrint FFPE and Blueprint® FFPE are not indicated as a standalone test to determine the outcome of disease, nor to suggest or infer an individual patient's likely response to therapy. Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine.

MammaPrint FFPE and Blueprint FFPE are for prescription use only.

### PHYSICIAN AUTHORIZATION

MammaPrint FFPE and Blueprint FFPE must be ordered by a physician or other qualified healthcare professional who has concluded that the test is medically necessary for the treatment of the patient and will provide prognostic and/or predictive information which has not been obtained already.

If any test is ordered as part of an authorized clinical trial, the order must be consistent with the applicable clinical trial protocol.

### SPECIMEN HANDLING AND SERVICE STANDARDS

Agendia will provide laboratory diagnostic testing upon the receipt of a valid physician (or qualified healthcare professional) order that includes the information necessary for Agendia to bill the patient or responsible third party, to the extent applicable, for the services provided.

Agendia shall handle and process the specimen(s) and perform the ordered laboratory testing professionally and to the best of its abilities in accordance with industry standards and applicable CLIA regulations. However, the client acknowledges that Agendia cannot and will not guarantee that the services will always be error-free. Agendia specifically disclaims any and all representations and warranties regarding its products and services, to the extent permitted by law, other than those expressly made in writing by Agendia, including the warranty literature for the product or service (if any). This disclaimer includes but is not limited to any representations or warranties as to the quality, reliability, fitness for purpose or any other feature of the products and/or services.

Multiple specimens will be tested sequentially.

- If the specimen generates a Low Risk MammaPrint FFPE result, the next tumor specimen(s) will be processed unless otherwise instructed.
- If the specimen generates a High Risk MammaPrint FFPE result, Agendia will consult with the ordering physician to determine how to proceed.

### CLIENT RESPONSIBILITIES

The client will provide Agendia with all data and other information required and necessary for Agendia to deliver the laboratory services.

The client warrants that the information provided to Agendia is correct and complete, and that it is entitled to provide Agendia with such information for the delivery of the laboratory services.

If any of the data provided is personal data or data otherwise protected by law, the client guarantees that with regard to such data, any and all applicable regulations and other legal requirements for the protection of privacy have been met and that Agendia is entitled to use and process such personal data.

The client shall give and make no warranty or representation on behalf of Agendia's products and/or services as to quality, reliability, fitness for purpose or any other feature of the products and/or services other than as explicitly set forth in writing by Agendia in the applicable warranty literature.

The client shall be solely liable for any claims arising out of or relating to the improper or faulty collection and/or handling of any specimen(s), any errors in transmission of information or data to Agendia, or any illegal or tortious act committed by the client, or his or her representatives, staff, affiliates, or associates or its employees, agents or assigns.

### MEDICARE COVERAGE CRITERIA

MammaPrint FFPE is a diagnostic test that analyzes the gene expression profile of FFPE breast cancer tissue samples to assess a patient's risk for distant metastasis. MammaPrint was prospectively validated as a microarray assay in the 6,693 patient MINDACT trial in early stage breast cancer, tumor size ≤ 5.0 cm, up to 3 positive lymph nodes and independent of receptor status.

By ordering MammaPrint FFPE, client has determined that the patient meets the applicable coverage criteria, however, if client believes the coverage criteria is not met, client shall provide to Agendia an advance beneficiary notice of non-coverage (ABN) signed by patient, in accordance with Medicare standards.

### FEES AND BILLING

Agendia shall bill patients and/or third-party payors (e.g., private insurance, Medicare, etc.) in accordance with applicable policies for the laboratory services performed. Client shall not bill any third party for any services performed by Agendia.

Blueprint is generally not reimbursable and may be billed with a nonbillable modifier.

If test(s) is being ordered as part of an authorized clinical trial in accordance with the clinical trial protocol, Agendia shall not bill any patient or third-party payor for the laboratory services.

*The client agrees that a legally binding agreement that includes Agendia, Inc.'s General Terms of Service (available here: <https://agendia.com/terms-conditions/general-terms-of-service/>) and these clinical laboratory testing requisition terms and conditions shall arise as soon as Agendia accepts the test order by email, written confirmation or the moment Agendia starts executing such an order, whichever occurs first.*